SEAPORT THERAPEUTICS, INC. COMMON STOCK

NASDAQ: SPTX (Seaport Therapeutics, Inc.)

Kemas kini terakhir: semalam, 11:30AM

18.05

-0.27 (-1.47%)

Penutupan Terdahulu 18.32
Jumlah Dagangan 284,274
Purata Dagangan (3B) 259,826
Modal Pasaran 966,226,432
Harga / Buku (P/B) 2.47
Julat 52 Minggu
14.85 (-17%) — 28.38 (57%)
Tarikh Pendapatan 2 Nov 2026
EPS Cair (TTM) -4.35
Jumlah Hutang/Ekuiti (D/E MRQ) 1.18%
Nisbah Semasa (MRQ) 17.48
Aliran Tunai Operasi (OCF TTM) -95.64 M

AISkor Stockmoo

0.0
Hutang rendah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Trend Perolehan info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Daripada analisis teknikal AI kami terhadap carta. info NA
Kekuatan Aliran info NA
Persediaan Teknikal info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Orang dalam menjual bersih baru-baru ini. info
Institusi bersih +1.10% daripada saham dalam pemfailan 13F terkini: 47 pemegang menambah, 18 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +18.4% dari 31 Aug hingga 30 Oct 2026, 17.4 hari untuk tutup (FINRA). info
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tiada tonggak mempunyai bacaan yang jelas, jadi skor tidak berubah.
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. info
Momentum jangka pendek menurun. info
Harga hampir dengan paras rintangan. info
Skor Akhir 0.00
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Seaport Therapeutics, Inc. - -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
SPTX 966 M - - 2.47 0.0
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 34.97%
% Dimiliki oleh Institusi 72.09%

Pemilikan

Nama Tarikh Syer Dipegang
Trv Gp Vi, Llc 30 Sep 2026 2,061,222
Canada Pension Plan Investment Board 30 Sep 2026 1,975,791
Foresite Capital Management Vi Llc 30 Sep 2026 1,779,521
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
ZOHAR DAPHNE - 21.97 -100,000 -2,197,000
Jumlah Keseluruhan Kuantiti Bersih -100,000
Jumlah Keseluruhan Nilai Bersih ($) -2,197,000
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 21.97
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
ZOHAR DAPHNE Pegawai 10 Nov 2026 Dibuang (-) 100,000 21.97 2,197,000

Institusi

Pemilikan institusi: 71.26%

Kedudukan Pemegang Saham
Bertambah 47 2,485,976
Berkurang 18 1,817,822
Baharu 26 298,039
Dijual habis 6 372,738

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 3,733,388 17.4
15 Oct 2026 3,718,915 17.9
30 Sep 2026 3,649,879 8.9
15 Sep 2026 3,148,881 20.7
31 Aug 2026 3,152,409 26.0
14 Aug 2026 3,012,877 25.1

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

Tarikh Jenis Butiran
05 Nov 2026 Yahoo Finance How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%
The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
02 Nov 2026 Yahoo Finance Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON, November 02, 2026--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress…
28 Oct 2026 Yahoo Finance Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
BOSTON, October 28, 2026--Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference…
25 Oct 2026 Yahoo Finance Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?
Seaport Therapeutics has just logged a sharp move in its share price over the past week, which naturally raises the question of whether the latest market enthusiasm lines up with what its book value supports. For anyone watching Seaport Therapeutics, the key issue now is how much of the current…
25 Oct 2026 Yahoo Finance Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage
Seaport Therapeutics (SPTX) has drawn fresh attention after recent trading left the shares at $20.61, with short term moves showing a mix of gains and pullbacks over the past week and month. Recent trading in Seaport Therapeutics points to choppy but generally improving sentiment, with a 7 day…
09 Oct 2026 Yahoo Finance PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress…
07 Oct 2026 Yahoo Finance PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance…
07 Oct 2026 Yahoo Finance Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance…
22 Sep 2026 Yahoo Finance PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.
22 Sep 2026 Yahoo Finance PureTech Health H1 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit…
14 Sep 2026 Yahoo Finance Seaport Therapeutics to Participate in September Investor Conferences
BOSTON, September 14, 2026--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional…
09 Sep 2026 Yahoo Finance Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON, September 09, 2026--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers…
31 Aug 2026 Yahoo Finance Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON, August 31, 2026--Seaport Therapeutics to present at Citi’s 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference…
26 Aug 2026 Yahoo Finance Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▼ Silang EMA menurun 3 sesi lalu · 17 Nov
Jangka pendek · EMA 7/20
EMA 7 hari melintas ke bawah EMA 20 hari: momentum jangka pendek berubah menurun.
▼ Silang EMA menurun 5 sesi lalu · 13 Nov
Jangka sederhana · EMA 20/50
EMA 20 hari melintas ke bawah EMA 50 hari: arah aliran jangka sederhana berubah menurun.

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda